The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Lignende værker

• Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
  af: van der Veer, Michael. S., et al.
  Udgivet: (2011)
• Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab
  af: Krejcik, Jakub, et al.
  Udgivet: (2017)
• Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
  af: Krejcik, Jakub, et al.
  Udgivet: (2016)
• Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
  af: Saltarella, Ilaria, et al.
  Udgivet: (2020)
• Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
  af: Nijhof, Inger S., et al.
  Udgivet: (2015)